Loss of full-length Brca1 in mammary epithelial cells of the mouse mammary tumor virus (MMTV)-Cre Brca1 conditional exon 11 deletion mouse model results in the development of mammary adenocarcinomas with similar genetic changes to those found in human BRCA1-mutation-related breast cancers. We used this experimental model to evaluate the chemopreventive effect of tamoxifen on the development of mammary preneoplasia and adenocarcinoma. No protective effects of tamoxifen administration on mammary cancer development were found. Instead, tamoxifen treatment significantly increased rates of mammary epithelial cell proliferation and the prevalence of mammary hyperplasia at 6 months of age. Tamoxifen-exposed mice developed adenocarcinomas at younger ages than control mice and a higher percentage of mice developed adenocarcinomas by 12 months of age. Both whole mouse and tissue culture cell models were used to test if loss of full-length Brca1 was associated with a relative increase in the agonist activity of tamoxifen. Tamoxifen induced increased ductal growth in MMTV-Cre Brca1 conditional mice compared to wild type. Estrogen receptor alpha (ERa) expression was downregulated in the tamoxifen-induced hyperplasias. Reducing BRCA1 levels in MCF-7 cells using siRNA resulted in a relative increase in the agonist activity of tamoxifen. Results suggest a model of mammary cancer progression in which loss of full-length Brca1 altered the agonist/antagonist activity of tamoxifen, resulting in tamoxifen-induced mammary epithelial cell proliferation with subsequent loss of ERa expression and development of ERa-negative hyperplasias and adenocarcinomas.
Introduction
Cre-lox-mediated conditional mouse models of Brca1-mutation-related breast cancer were first introduced in 1999 (Xu et al., 1999) . The mouse mammary tumor virus (MMTV)-Cre transgene utilized to induce tissue-specific loss of full-length Brca1 in mammary epithelial cells first induces recombination and loss of full-length Brca1 during late embryogenesis (Wagner et al., 1997 (Wagner et al., , 2001 ). Haploid loss of p53 promotes mammary cancer development in this model (Brodie et al., 2001) . The adenocarcinomas developing in this model demonstrate invasive features characteristic of human breast cancer and exhibit estrogen-independent growth similar to the majority of BRCA1-mutation-related human breast cancers (Brodie et al., 2001 ). The adenocarcinomas demonstrate different molecular signatures. Reports to date document overexpression of either ErbB2, cyclin D1 or c-myc in addition to loss of functional p53 (Brodie et al., 2001) .
There are a variety of hormonal manipulations (ovariectomy, selective estrogen response modifier (SERM) treatment, aromatase treatment) that have proven to be highly effective in the treatment of estrogen receptor alpha (ERa)-positive breast cancer and can cause the regression of even relatively large tumors (Chlebowski, 2002; Jordan, 2004) . In contrast, these treatments have been considered to be ineffective in the treatment of ERa-negative tumors. In humans, the majority of BRCA1-mutation-related breast cancers are ERa negative , but two lines of evidence point to a possible role for estrogen in the early stages of cancer progression. First, a number of studies have shown that ovariectomy, with follow-ups of 6-10 years, decreases the occurrence of breast cancer almost 50% and greater degrees of protection are found when it is performed at younger ages (Meijers-Heijboer et al., 2001; Rebbeck et al., 2002) . We initially repeated these studies in the present MMTV-Cre Brca1 conditional exon 11 mouse model and found that ovariectomy decreased the production of mammary tumors beginning roughly 5 months after bilateral oophorectomy (Bachelier et al., 2002) . The efficacy of ovariectomy in this model was also associated with reduced development of the mammary gland.
Second, a direct repressive function of BRCA1 on ERa transcriptional activity has been described (Fan et al., 1999 (Fan et al., , 2001 Zheng et al., 2001) . Owing to this, it has been hypothesized that tamoxifen, an SERM, might have a protective role at early stages of cancer progression even if the majority of cancers are ERa negative. Clinical studies published to date demonstrate mixed results (Narod et al., 2000; Schrag et al., 2000; King et al., 2001; Robson, 2002) , where one study showed efficacy (Narod et al., 2000) and a second study, albeit with low tumor numbers, showed minor enhancement (King et al., 2001) .
Tamoxifen is a mixed agonist/antagonist (Gallo and Kaufman, 1997). In normal mice, tamoxifen treatment results in regression of mammary ductal structures (Kotoula et al., 1993) and, tamoxifen, unlike chronic estrogen treatment, does not downregulate levels of nuclear-localized ERa (Cheng et al., 2004) . It does, however, downregulate levels of nuclear-localized ERb (Cheng et al., 2004) . Tamoxifen can prevent progression of ERa-negative cancers in certain mouse models (Osborne et al., 1990; Yoshidome et al., 2000; Yang et al., 2003) . The timing of tamoxifen administration during disease progression may be important as tamoxifen promotes cancer development in MMTVErbB2 transgenic mice when delivered later during the course of disease (Menard et al., 2000) .
In contrast to the relatively clear data demonstrating the efficacy of ovariectomy in human BRCA1 mutation carriers, the data with tamoxifen have been more equivocal. This study was initiated to determine whether or not tamoxifen treatment would prevent progression of mammary cancer in a genetically defined mouse model with loss of full-length Brca1 and haploid insufficiency of p53.
Results

Tamoxifen treatment increased the prevalence of mammary hyperplasia in Brca1
Co/Co MMTV-Cre/p53 þ /À female mice
Placebo-treated Brca1
Co/Co MMTV-Cre/p53 þ /À female mice demonstrated a pattern of cancer progression characterized by areas of normal-appearing mammary histology, with focal areas of mammary hyperplasia in 50% of the mice by 6 months of age (Figure 1 ). Hyperplastic alveolar nodules (HANs) developed in 90% of the mice and adenocarcinomas developed in 35% of the mice by 12 months of age. To determine if tamoxifen treatment altered development of hyperplasia, the prevalence of hyperplasia was compared in tamoxifen-and placebo-treated 6-month-old mice. Unexpectedly, tamoxifen treatment significantly increased the prevalence of mammary hyperplasia at 6 months of age from 50% in the placebo-treated mice to 100% in the tamoxifen-treated mice (Figure 2 ) (w 2 , Po0.05). Consistent with previously published results (Kotoula et al., 1993) , wild-type control female mice treated with the same tamoxifen pellets utilized for the Brca1
Co/Co MMTV-Cre/p53 þ /À female mice demonstrated mammary ductal regression (data not shown).
Tamoxifen treatment increased the rate of mammary epithelial cell proliferation
To test if the increased prevalence of mammary hyperplasia was associated with an increase in the rate of mammary epithelial cell proliferation, proliferative indices were compared in placebo-and tamoxifentreated 6-month-old mice both in normal-appearing (Table 1) . The mean mammary epithelial cell proliferative indices of tamoxifen-treated mice were significantly higher in both normal-appearing ducts (1072%) (mean7standard error (s.e.) and areas of hyperplasia (1171%) than in placebo-treated mice (normal-appearing ducts: 271% and hyperplasias: 474%) (Kruskal-Wallis, Po0.012, Table 1, Figure 3a and b). There was no significant differences in the mean apoptotic index between the placebo-and tamoxifen-treated groups in either the normal-appearing ducts or the areas of hyperplasia (o1% for both) (Figure 3c and d) . In wild-type mice, chronic estrogenic stimulation, but not chronic tamoxifen treatment, results in downregulation of nuclearlocalized ERa. In contrast, chronic tamoxifen stimulation results in downregulation of nuclear-localized ERb but not ERa (Saji et al., 2000; Cheng et al., 2004) . We hypothesized that if the relative agonist activity of tamoxifen was increased by loss of full-length Brca1, there would be loss of nuclear-localized ERa with retention of nuclear-localized ERb in the hyperplasias of the tamoxifen-treated Brca1
Co/Co MMTV-Cre/p53 þ /À mice. In support of this hypothesis, immunohistochemical studies demonstrated a significant loss of nuclear-localized ERa but retention of nuclear-localized ERb in the hyperplastic lesions of tamoxifen-treated mice (Kruskal-Wallis, Po0.002) ( Table 2, Figure 3e and f). There was no change in progesterone receptor (PR) expression following tamoxifen exposure (data not shown).
Tamoxifen treatment increased the incidence of adenocarcinoma
To establish whether or not the increased prevalence of hyperplasia found in the tamoxifen-treated mice was (Figure 4a  and b) . Tamoxifen treatment did not alter significantly the differentiation status, or tumor multiplicity. As overexpression of either ErbB2 or epidermal growth factor receptor (EGFR) has been associated with tamoxifen resistance (Kurokawa and Arteaga, 2003) , steady-state levels of ErbB2 and EGFR were evaluated in the adenocarcinomas of tamoxifen-treated mice and compared to the levels found in adenocarcinomas from Co/Co MMTV-Cre/p53 þ /À female mice. Shown are representative immunoblots of total protein (40 mg protein/lane) samples of adenocarcinomas from six individual mice after administration of either placebo (lanes 1-3) or tamoxifen (lanes 4-6). Expression of ErbB2 and EGFR were found in 66 and 33%, respectively, of the adenocarcinomas from tamoxifen-treated mice and 60% and 60, respectively, of the adenocarcinomas from placebo-treated mice. RXRa expression was found in 75% of the adenocarcinomas from tamoxifen-treated mice and 100% of the adenocarcinomas from placebo-treated mice. The differences were not statistically significant (w 2 , PX0.05) placebo-exposed mice. There were no statistically significant differences in the prevalence of either ErbB2 or EGFR overexpression between the two groups ( Figure 4c ). This indicates that the increased incidence of adenocarcinoma development in the tamoxifentreated mice was not due to selection for high expression of ErbB2 or EGFR. We evaluated expression levels of the retinoid X receptor alpha (RXRa) in both adenocarcinomas and hyperplastic mammary tissue from placebo-and tamoxifen-treated mice because RXRselective ligands have chemopreventive activity and have been shown to improve response in combination with tamoxifen (Bischoff et al., 1999; Grubbs et al., 2003) . Both the hyperplastic mammary tissue from 6-month-old mice (data not shown) and a significant proportion of the adenocarcinomas (Figure 4c ) demonstrated expression of this receptor, suggesting that this could be an alternative therapeutic approach for mammary cancers that arise from loss of Brca1 function.
Decreased expression levels of Brca1 were associated with a relative increase in the agonist activity of tamoxifen
The MCF-7 mammary epithelial cell tissue culture cell model was used to test if a decrease in BRCA1 expression levels could be linked to an increase in the agonistic activity or a decrease in the antagonistic activity of tamoxifen. Steady-state levels of BRCA1 protein were reduced significantly using siRNA (Figure 5a ). Consistent with previously published results (Fan et al., 1999 (Fan et al., , 2001 , decreased levels of BRCA1 expression in this model resulted in increased levels of estrogen response element (ERE)-mediated luciferase activity in response to 17-b estradiol (Figure 5b) . Similarly, reducing BRCA1 expression levels resulted in a modest but significant increase in luciferase activity in response to tamoxifen consistent with a relative increase in the agonist activity of tamoxifen and a decrease in the relative amount of antagonist activity (Figure 5c ). Reducing BRCA1 expression levels using siRNA had no effect on steady-state expression levels of ERa ( Figure 6 ).
Discussion
This paper describes the effect of tamoxifen on mammary cancer development in the MMTV-Cre Brca1 conditional exon 11 deletion mouse model. Significantly, tamoxifen was not protective in this model when administered at 4 months of age following a first pregnancy. In contrast, tamoxifen stimulated mammary epithelial cell proliferation, ductal growth and promoted the development of mammary adenocarcinomas, acting more like a growth agonist than an antagonist. This increase in mammary epithelial cell proliferation and ductal growth following tamoxifen treatment in Brca1-altered mice was the opposite of the effects in tamoxifentreated wild-type mice. Consistent with these in vivo observations, a relative increase in the agonist activity of tamoxifen was found when BRCA1 expression levels were decreased in tissue culture cells. Tamoxifen routinely acts as a growth antagonist for the mammary gland by interrupting ERa signal transduction (Kotoula et al., 1993) . However, in the Figure 5 Reducing BRCA1 expression in MCF-7 cells using siRNA resulted in a relative increase in the agonist activity of tamoxifen and a decrease in the relative amount of antagonist activity. Reduction of BRCA1 expression levels by siRNA (a). Immunoblot analysis of BRCA1 protein expression in MCF-7 cells treated with no siRNA, control siRNA or BRCA1-siRNA. a-Actin was used as a control for loading and transfer. ER transcriptional activity in MCF-7 cells pretreated with BRCA1-siRNA, control siRNA or no siRNA in the presence or absence of 17-b estradiol or tamoxifen for 24 h shown in (b) and (c), respectively. Results obtained from the same set of experiments but shown in different panels due to the differences in scales. Luciferase values are expressed relative to the absolute control value (i.e. no siRNA, no E2 or tamoxifen). Values are means7s.e.m.'s for n ¼ 4 replicate wells Figure 6 BRCA1-siRNA has no effect on ERa expression. Subconfluent proliferating MCF-7 cells were treated with BRCA1-siRNA, control siRNA (50 nM Â 72 h) or no siRNA (vehicle only), and then incubated 717-b estradiol (E2, 10 nM) (a) or 7tamoxifen (Tam, 100 nM) (b) for T ¼ 24 h. The cells were then harvested to detect BRCA1, ERa and a-actin (control for loading and transfer) uterus and bone, the agonist activity of tamoxifen dominate (Dutertre and Smith, 2000) . Additionally, the use of tamoxifen in breast cancer patients has been associated with 'tamoxifen flare', a condition in which a transient increase in tumor growth follows the initial administration of tamoxifen (Plotkin et al., 1978; Veldhuis and Santen, 1979; Reddel and Sutherland, 1984) . Previous studies attribute this transitory growth of the cancer to a relative enhancement of the agonist activity of tamoxifen before steady-state therapeutic levels are achieved. Several mechanisms have been proposed to explain why tamoxifen may act as an antagonist in some tissues and act as an agonist in others, including cell-specific tamoxifen-induced changes in ERa conformation or modifications that alter the ability of ERa to interact with coactivators or corepressors, expression levels of coactivators or corepressors, or activity of other intracellular signaling pathways (Dutertre and Smith, 2000; Graham et al., 2000; McDonnell et al., 2002; Heldring et al., 2004; Jordan, 2004; Smith and O'Malley, 2004) . The agonist activity of tamoxifen is increased when the coactivator AIB1/SRC-3 or its isoform AIB1-D3 is overexpressed (Reiter et al., 2004) and tamoxifen increases steady-state protein levels of SRC-1 and AIB1/SRC-3 (Lonard et al., 2004) . Higher levels of AIB1 expression in human breast cancer have been associated with poorer outcome following tamoxifen therapy .
Brca1-mediated changes in coactivator or corepressor expression levels or activity could be a possible explanation for the shift to tamoxifen agonism. Loss of BRCA1 has been reported to increase ERa signaling by reducing expression levels of p300 (Fan et al., 2002) . Longer polyglutamine repeat length in the AIB1 gene has been associated with a higher risk of breast cancer development in carriers of BRCA1 mutation, raising the possibility that the AIB1 gene may collaborate with BRCA1 loss in the development of breast cancer (Rebbeck et al., 2001; Kadouri et al., 2004) .
In humans, loss of function of one BRCA1 allele has been associated with a relative increase in PR A levels, alterations in ERa-regulated gene expression, but a normal ERa expression pattern (Mote et al., 2004) . Similarly, in the study reported here, a normal pattern of nuclear-localized ERa expression was found in the normal-appearing mammary ductal cells. However, the abnormal foci of proliferating mammary epithelial cells that developed in the tamoxifen-exposed mice did not demonstrate nuclear-localized ERa. The adenocarcinomas that develop in this model also are predominantly ERa negative (Brodie et al., 2001) . Taken together, these observations suggest that while estrogenic pathways may act as an initial stimulus for abnormal proliferation, cancer progression may be maintained by ERaindependent mechanisms. This is consistent with observations made in BRCA1-related human breast cancer in which ovariectomy is protective, but the majority of cancers that develop are ERa negative (Kauff et al., 2002; Moller et al., 2002; Rebbeck et al., 2002; Foulkes et al., 2004) .
Effective chemoprevention for BRCA1-mutation-related cancer in women is an important clinical goal. Data to date from clinical trials are equivocal about the value of tamoxifen for chemoprevention in this population (Narod et al., 2000; Schrag et al., 2000; King et al., 2001; Robson, 2002 ). An important difference between these trials and the experiments performed here is that in the mouse model full-length Brca1 expression is lost, while in the human studies, the women have loss or mutation of just one allele in the majority of their normal-appearing mammary epithelial cells and loss or mutation of all BRCA1 function only in a subset of these cells or in the carcinomas (Cavalli et al., 2004) . Additional experiments will need to be performed to determine if shifts in the agonist/antagonist activity of tamoxifen are associated with any of the BRCA1 mutations found in humans or with reduced but not absent BRCA1 expression. The results do point towards the need to develop alternative chemopreventive approaches. One possibility based on the experiments here would be to exploit RXRa as a chemopreventive target (Brown and Lippman, 2000; Sporn and Suh, 2000) . Other targets and approaches for combination or intermittent therapy also need to be investigated further (Rendi et al., 2004) .
In summary, this study demonstrates that loss of Brca1 can alter the agonist/antagonist activity of tamoxifen in mammary epithelial cells and illustrates that cancer progression in a mouse model of Brca1-mutation-related mammary adenocarcinoma proceeds through sequential steps from ERa-negative hyperplastic proliferative foci through HANs to adenocarcinoma.
Materials and methods
Mice and genotyping
Brca1 conditional knockout mice carrying the MMTV-Cre recombinase gene in a p53 heterozygous background (Xu et al., 1999) were maintained on a C57Bl/6 genetic background. Nontransgenic C57Bl/6 mice were used as controls. All mice were maintained in accordance with institutional guidelines approved by the Georgetown University Animal Care and Use Committee. The presence of the floxed Brca1 alleles, the absence of wild-type Brca1 alleles and the presence of the MMTV-Cre transgene were identified using polymerase chain reaction (PCR) on tail DNA as described previously (Wagner et al., 1997; Xu et al., 1999) . The p53 heterozygote allele was identified using a modification of previously published techniques (5 0 primer: p53 wild-type allele -forward primer (5 0 -CTGTCTTCCAGATACTCGGGATAC-3 0 ); reverse primer (5 0 -CCAATGGTGCTTGGACAATGTG-3 0 ). p53 knockout allele -forward primer (5 0 -CTGTCTTCCAGA TACTCGGGATAC-3 0 ); reverse primer: (5 0 -ATCGCCTTC TATCGCCTTCTTGACGAGTTC-3 0 )). In all, 35 PCR cycles were run (45 s at 941C; 1 min 20 s at 571C; 3 min at 721C) (Donehower et al., 1992; Xu et al., 1999) .
Tamoxifen treatment studies
Mice were bred at 2 months of age. After parturition, female mice were anesthetized and implanted subcutaneously with a 25 mg 60-day constant release tamoxifen pellet (n ¼ 31) or a placebo pellet (n ¼ 28) (Innovative Research of America, Sarasota, FL, USA). For studies of mammary hyperplasia, mice were euthanized at 6 months of age (n ¼ 6 tamoxifen treated and n ¼ 6 placebo treated) and necropsied. For mammary adenocarcinoma studies (n ¼ 25 tamoxifen treated and n ¼ 22 placebo treated), mice were monitored weekly for the development of primary palpable tumors and then euthanized when a palpable tumor reached 1 cm 3 or by 12 months of age, whichever came first. Tumor development was recorded as the animal age when a tumor was first detected by palpation. Complete necropsies were performed to examine for the presence or absence of nonpalpable tumors, more than one tumor and metastases. Mammary tissue, mammary cancer tissue and tissue containing metastases were removed and processed for whole mount, formalin fixed for histology or immediately frozen in liquid nitrogen and stored at À801C for gene expression analysis as appropriate.
Whole-mount analysis, histological studies, in situ detection of apoptosis and immunohistochemistry Mammary tissue and adenocarcinoma specimens were fixed in 10% buffered formalin overnight at 41C and embedded in paraffin using standard techniques. Sections (5 mm) were cut for hematoxylin and eosin (H&E) staining and immunohistochemistry. Eight nonadjacent sections from each mammary gland of each mouse were examined for the presence or absence of normal ductal structures, hyperplasia and adenocarcinoma. In situ detection of apoptotic cell nuclei was performed using the ApopTag Apoptosis Detection Kit (Intergen Company, Purchase, NY, USA) and the apoptotic index determined (Li et al., 1996) . Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) expression was performed using the EPOS PCNA Immunostaining system (U7032, DAKO, Carpinteria, CA, USA) and the proliferative index (Tilli et al., 2003) determined separately for the normal-appearing ducts and the areas of hyperplasia in the Brca1
Co/Co MMTV-Cre/p53 þ /À female mice. ERa, ERb and PR immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections using the mouse on mouse (M.O.M) peroxidase kit (PK-2200, Vector Laboratories Inc., Burlingame, CA, USA). Tissues sections were deparaffinized and rehydrated. For ERa immunohistochemistry, antigens were exposed to preheated 1 Â High pH Target Retrieval Solution (S3307, Dako) for 25 min. For ERb and PR immunohistochemistry, slides were pressure cooked for 4 min and immersed in preheated 1 Â High pH Target Retrieval Solution (Dako). Slides were allowed to cool for an additional 20 min in the retrieval solution, quenched with 3% hydrogen peroxide, blocked with mouse IgG-blocking reagent, incubated with M.O.M diluent and a 1 : 25 dilution of the ERa antibody (IM2133, Beckman Coulter Immunotech, Miami, FL, USA) for 1 h at room temperature, or a 1 : 100 dilution of the ERb antibody (GTX70174, GeneTex Inc., San Antonio, TX, USA) for overnight at 41C, or a 1 : 100 dilution of the PR antibody (NCL-L-PGR-AB, Novacastra, UK) for 1 h at room temperature. The tissues were exposed to M.O.M biotinylated antimouse IgG reagent for 10 min at room temperature, M.O.M elite stain for 30 min, then stained with diaminobenzidine peroxidase substrate kit (SK-4100, Vector Laboratories Inc.) for 5 min and counterstained with hematoxylin, and then mounted with GVA-mount (Vector Laboratories Inc.). Digital photographs were taken using the Nikon Eclipse E800M microscope setup with Nikon DMX1200 software (Nikon Instruments Inc., Melville, NY, USA).
Immunoblot analysis and semiquantitative RT-PCR of mammary tissue
Frozen mammary adenocarcinoma was homogenized in protein lysis buffer to extract whole proteins (n ¼ 17). Protein concentration was quantified by bicinchoninic protein assay (Pierce, Rockford, IL, USA). Protein (40 mg) from each sample was solubilized in sample dilution buffer, separated by denaturing 8% Tris-glycine gels (Invitrogen Life Technologies, Carlsbad, CA, USA) and electrophoretically transferred to polyvinylidene difluoride membranes for immunoblot analysis. Membranes were blocked in 5% nonfat dry milk in Trisbuffered saline and 1% Tween (TBS-T) overnight at 41C. Membranes were incubated with primary antibodies against ErbB2 (sc-284, Santa Cruz, Santa Cruz, CA, USA), EGFR (sc-03, Santa Cruz) or RXRa (sc-553, Santa Cruz) for 1 h at room temperature and washed with TBS-T. Bound antibody was detected by incubation with a 1 : 5000 dilution of a horseradish peroxidase-linked anti-rabbit secondary antibody (sc-2004; Santa Cruz) for 1 h at room temperature. Immunoreactive protein was detected with the enhanced chemiluminescence (ECL) plus Western blotting detection kit (RPN2133, Amersham Biosciences, Piscataway, NJ, USA). Total RNA was isolated by Trizol extraction (Invitrogen, Carlsbad, CA, USA) from mammary gland tissue snap-frozen at the time of necropsy, quantified on a spectrophotometer and cDNA synthesis performed. PR mRNA was detected using forward primer (5 0 -CATGTCAGTGGACAGATGCT-3 0 ) and reverse primer (5 0 -ACTTCAGACATCATTTCCGG-3 0 ).
siRNA treatment and immunoblot analysis of MCF-7 cells
Subconfluent proliferating MCF-7 cells were treated with BRCA1-siRNA, control-siRNA (50 nM Â 72 h) or no siRNA (vehicle only) before being harvested and subjected to Western blotting to detect BRCA1, ERa or a-actin. The sequences of the siRNAs used were: BRCA1-siRNA-3 (5 0 -AATGC-CAAAGTAGCTAATGTA-3 0 ) and scrambled-sequence control siRNA (5 0 -GTCACGATAAGACAATGATAT-3 0 ) (Xiong et al., 2003) . All siRNAs were chemically synthesized by Dharmacon Inc. For siRNA treatments, subconfluent proliferating cells were treated with each siRNA (50 nM), using siPORT Amine reagent (Ambion). The cells were incubated with siRNA for 72 h (to reduce BRCA1 protein levels to o25% of control) prior to the start of the experiment. The control siRNA has no effect on BRCA1 levels (Xiong et al., 2003) ; neither siRNA is toxic to the cells under these experimental conditions, as determined using MTT assays. Equal aliquots of total protein (50 mg/lane) were electrophoresed on a 4-13% SDS-polyacrylamide gradient gel, transferred to nitrocellulose membranes (Millipore) and blotted using primary antibodies directed against human BRCA1 (sc-642, rabbit polyclonal, Santa Cruz, 1 : 200), ERa (sc-8002, mouse monoclonal, Santa Cruz, 1 : 400) and a-actin (sc-1616, goat polyclonal, Santa Cruz, 1 : 500). After incubation with the appropriate horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences), immune complexes were visualized by using the ECL detection system (Amersham Biosciences), with colored markers (BioRad, Hercules, CA, USA) as molecular size standards.
ER transcriptional assays
Subconfluent proliferating MCF-7 cells in 24-well dishes were pretreated with BRCA1-siRNA, control (scrambled-sequence) siRNA (50 nM Â 72 h) or no siRNA (vehicle only); the cells were then transfected overnight (using Lipofectamine TM , Invitrogen Life Technologies) with the estrogen-responsive luciferase reporter ERE-thymidine kinase (TK)-luciferase gene (Luc), which consists of the vitellogenin A2 ERE upstream of a minimal TK promoter and Luc (0.25 mg plasmid DNA per well) as described previously (Fan et al., 2002) . The cells were then washed, allowed to recover for a few hours and then treated 717-b estradiol (E2) (10 nM) and 7tamoxifen (10, 100 and 1000 nM) for 24 h in serum-free phenolphthalein-free DMEM. The cells were then harvested for luciferase assays. Luciferase values expressed relative to the absolute control value (i.e. no siRNA, no E2 or tamoxifen). Values are means7s.e.m. for n ¼ 4 replicate wells. A second independent experiment gave similar results.
Statistical analyses
Nonparametric data were analysed using Kruskal-Wallis, Mann-Whitney and w 2 tests. The time to first palpable tumor in the different groups was compared using a Kaplan-Meier test. Po0.05 was considered statistically significant.
